In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The State of Laboratory Unions

Executive Summary

Hospital laboratory consolidation, underway for several years, is having mixed success as the market shifts. For suppliers, things are unlikely to settle down soon. Successful labs claim to be committed to a common vision and to swift action to institute painful changes. But other labs are stymied by politics, lack of top management support, and reluctance to make difficult decisions quickly. Manufacturers' expectations that consolidation would lead to standardization of equipment and a winner-take-all mentality are starting to come to pass. But the customer base continues to be in more flux than expected.

You may also be interested in...



Clinical Laboratories' Amazing Comeback

A variety of factors, ranging from consolidation to the emergence of genomics, has helped resurrect clinical labs from near death. The nation's two largest labs, LabCop. and Quest, have seen their stock prices shoot up a staggering 600% in the past three years, while a cadre of more specialized labs has ridden their coattails. These labs are looking to genomics to sustain their renaissance, as existing drivers shift and maintaining their growth rate gets tougher.

GPOs Rethink Diagnostics

As major GPOs come under pressure from a variety of sources they are refining their approach to laboratory purchasing, with ramifications for suppliers. Groups are getting tougher on compliance and contracting with fewer lab vendors but the trade-off is less choice for lab members. The more the purchasing process restricts vendors, the more it benefits a few at the expense of many.

Rethinking Diagnostics Contracts

The nation's largest GPOs are rethinking the way they contract with diagnostics industry suppliers in light of new workstation consolidation coming on the market. Novation is considering combining immunoassay and clinical chemistry onto one contract; Premier is planning to hold a conference for members on the future of diagnostics and then a meeting of its laboratory task force to think of how to use new technologies.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel